Fecal Microbiota Transplantation (FMT) & Autism Spectrum Disorder

Clinical trials with Fecal Microbiota Transplantation (FMT) have been performed in patients with Autism Spectrum Disorder and showed beneficial effects on neurological symptoms.
Vendrik et al. 2020

A small open-label clinical trial evaluated the impact of Microbiota Transfer Therapy (MTT) on gut microbiota composition and GI and ASD symptoms of 18 ASD-diagnosed children.
Kang et al. 2017a Microbiome 5(1): 10

The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
Kang et al. 2017a Microbiome 5(1): 10

Improvements persisted eight weeks after treatment.
Kang et al. 2017a Microbiome 5(1): 10

Similarly, clinical assessments showed that behavioral ASD symptoms improved significantly and remained improved eight weeks after treatment ended.
Kang et al. 2017a Microbiome 5(1): 10

Bacterial and phagedeep sequencing analyses revealed successful partial engraftment of donor microbiota and beneficial changes in the gut environment.
Kang et al. 2017a Microbiome 5(1): 10

Specifically, overall bacterial diversity and the abundance of Bifidobacterium, Prevotella, and Desulfovibrio, among other taxa, increased following FMT, and these changes persisted after treatment stopped (followed for eight weeks).
Kang et al. 2017a Microbiome 5(1): 10

see also:
Fecal Microbiota Transplantation (FMT) & Preclinical/Clinical data